Response to letter ‘Reassessing safety signals in low-dose thrombolysis for intermediate-high-risk pulmonary embolism’
Cardiovascular Research · 17.10.2026
DOI: 10.1093/cvr/cvag208 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cardiovascular Research, online erschienen am 17.10.2026. Verfasst von J Kjaergaard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
We thank Dr Ghotraa and colleagues for their insightful letter and are pleased to offer our perspective on the issues raised. The safety profile of treatment strategies using low-dose thrombolysis—whether administered intravenously or by catheter, including ultrasound-assisted catheter-directed thrombolysis—remains a key priority in patients with intermediate-high-risk pulmonary embolism (PE). Trials suggest that the observed risk associated with the disease may be lower than previously estimated raising concerns that current risk-stratification tools may overestimate the need for aggressive thrombolytic therapy.1,2 Reducing dose of thrombolytics as implemented in the STRATIFY trial3 and the Hi-PEITHO trial4 resulted in an overall very low risk of bleeding, including intracranial haemorrhage (ICH). While the 2014 PEITHO trial reported 2% risk of ICH with full-dose thrombolysis,5 the recent trials using 18–20 mg of alteplase administered over 6–7 h3,4 appear to be associated with a lower risk of ICH and severe bleeding. We agree that current evidence does not support the notion that catheter-based thrombolysis confers a lower bleeding risk compared with intravenous administration; bleeding risk is more likely related to the dose of thrombolytics rather that the route of administration. Dr Ghotraa and colleagues correctly note that the recent trials enrolled patients with a different overall risk profile, but we believe that this difference is unlikely to explain the absence of ICH in the Hi-PEITHO trial.4
Autor:innen und Institutionen
- Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Denmark.
ORCID-Profile: J Kjaergaard, J Carlsen
Zitieren
APA
Kjaergaard, J., Bang, L. E., Ersbøll, M. K., & Carlsen, J. (2026). Response to letter ‘Reassessing safety signals in low-dose thrombolysis for intermediate-high-risk pulmonary embolism’. Cardiovascular Research. https://doi.org/10.1093/cvr/cvag208
Vancouver
Kjaergaard J, Bang LE, Ersbøll MK, Carlsen J. Response to letter ‘Reassessing safety signals in low-dose thrombolysis for intermediate-high-risk pulmonary embolism’. Cardiovascular Research. 2026. doi:10.1093/cvr/cvag208
BibTeX
@article{Kjaergaard2026,
author = {Kjaergaard, J and Bang, L E and Ersbøll, M K and Carlsen, J},
title = {Response to letter ‘Reassessing safety signals in low-dose thrombolysis for intermediate-high-risk pulmonary embolism’},
journal = {Cardiovascular Research},
year = {2026},
doi = {10.1093/cvr/cvag208}
}
EUVIMED